Skip to main content

LifeSensors To Launch Ubiquitin Traps Next Month


LifeSensors this week announced it has exclusively licensed on a global basis high-affinity ubiquitin traps developed by Manuel Rodriguez and will launch them in October.

Rodriguez is the group leader in proteomics at CIC bioGUNE, a bioscience research center in Spain. The traps, called Tandem-repeated Ubiquitin Binding Entities, or TUBEs, are based on protein domains with an affinity for ubiquitin and were developed to purify ubiquitylated proteins, the company said in a statement. TUBEs display up to a 1,000-fold increase in affinity for poly-ubiquitin moieties over a single ubiquitin binding domain.

Ubiquitin pathway proteins play significant roles in a number of diseases such as neurodegenerative ailments and cancer. Ubiquitylated proteins are unstable, however, and the ubiquitylation state of many proteins is poorly characterized. TUBEs, LifeSensors said, fills this void in ubiquitin research, by allowing the identification of ubiquitin-modified proteins that cannot otherwise be detected.

Proteins can be purified from cells, tissues, and organs with TUBES, the company added.

LifeSensors, based in Malvern, Penn., discovers, develop, and manufactures SUMO-based proteins expression technologies and ubiquitin research tools.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.